Management ChangeJun 2, 2026, 04:52 PM
Cue Biopharma Appoints New Legal Officer, Accounting Officer, Directors; Board Size Reduced
AI Summary
Cue Biopharma, Inc. announced significant changes to its Board of Directors and executive leadership. Four directors mutually agreed to resign, while Daniel Camardo and Viola Meehan were appointed as new directors, leading to a reduction in the Board's size from seven to five members. Additionally, Sumita Ray was appointed Chief Legal & Compliance Officer and Corporate Secretary, and Michael Meluzio was named Vice President, Principal Accounting Officer.
Key Highlights
- Four directors, Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen, resigned from the Board.
- Sumita Ray, JD, appointed Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
- Michael Meluzio appointed Vice President, Principal Accounting Officer, effective June 1, 2026.
- Daniel Camardo and Viola Meehan appointed as new directors to the Board.
- Board size reduced from seven directors to five directors, effective June 1, 2026.
- Mr. Camardo appointed chair of the Nominating and Corporate Governance Committee.
- Ms. Meehan appointed chair of the Audit Committee.
Price Impact
More from CUE